Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Epidemiological Disease Burden and Cost of Illness of Psoriasis in the US

Speaker(s)

Gupta A1, Bhalani S2, Chopra A3, Jabin F2, Gaur A4, Kukreja I5, Roy A6, Brooks L7, Sulzicki M8, Verma V9, Pandey S10
1Optum, Eden Prairie, MN, USA, 2Optum Global Solutions, UHG, New Delhi, India, 3Optum Global Solutions, India, Gurugram, HR, India, 4Optum, Gurugram, HR, India, 5Optum Global Solutions, India, New Delhi, DL, India, 6Optum, Gurgaon, HR, India, 7Optum, Basking Ridge, NJ, USA, 8Optum, Trumbull, CT, USA, 9Optum Global Solutions, India, Gurgaon, HR, India, 10Optum Global Solutions, India, noida, gautam buddha nagar, UP, India

Presentation Documents

OBJECTIVE: Psoriasis is a very common disease that affects almost 2% of the world’s population and 7.5 million of the U.S. population. The cost of illness is an important metric to study for psoriasis because it can explain the economic burden of the disease. Aim of this study to determine and comprehend the disease burden of psoriasis, as well as the cost of psoriasis illness in the United States. METHOD: The burden of disease of psoriasis was estimated based on demographic and health statistics available from 2016-2020, using the claims data available on one of the largest US managed care organizations representing about 15% of commercially insured lives and 23% of Medicare Part D beneficiaries. We have identified patients with the ICD codes and checked for the total cost for each year. The total cost of disease is measured by the inclusion of medical costs and pharmacy costs. RESULT: We have found that total number of patients suffering from psoriasis has increased 1.16% from the years 2016-2020 and reached to 230,056 in 2020. The total medical cost and pharmacy cost of psoriasis was found $1.7 billion in 2020, which has increased over the years. Cost is not adjusted for inflation. CONCLUSION: The consequences of this cross-sectional study suggest that psoriasis remains a very common and immune mediated chronic inflammatory disease. Prevalence of psoriasis was 9 in 2016 and has increased to 10.5 in 2020 per thousand population in claims data. This research can help to identify the burden of disease and can support other research, policies, and health programs.

Code

EPH142

Topic

Economic Evaluation, Epidemiology & Public Health, Study Approaches

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas